Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast

Background There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE). Methods Immunofluorescence multiplexing (MxIF) was used to image and quantify 32 cellular biomarkers in FFPE DCIS tissue microarrays. Over 75,000 DCIS cells from 51 patients (media...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	British journal of cancer Ročník 124; číslo 6; s. 1150 - 1159
Hlavní autori:	Badve, Sunil S., Cho, Sanghee, Gökmen-Polar, Yesim, Sui, Yunxia, Chadwick, Chrystal, McDonough, Elizabeth, Sood, Anup, Taylor, Marian, Zavodszky, Maria, Tan, Puay Hoon, Gerdes, Michael, Harris, Adrian L., Ginty, Fiona
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 16.03.2021 Nature Publishing Group
Predmet:	631/67/1347 692/53/2422 Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer Research Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - therapy Carcinoma, Intraductal, Noninfiltrating - metabolism Carcinoma, Intraductal, Noninfiltrating - pathology Carcinoma, Intraductal, Noninfiltrating - therapy Cluster analysis Combined Modality Therapy Drug Resistance Epidemiology ErbB-2 protein Female Follow-Up Studies Humans Immunofluorescence Mastectomy - methods Middle Aged Molecular Medicine Oncology Prognosis Retrospective Studies Survival Rate
ISSN:	0007-0920, 1532-1827, 1532-1827
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Background There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE). Methods Immunofluorescence multiplexing (MxIF) was used to image and quantify 32 cellular biomarkers in FFPE DCIS tissue microarrays. Over 75,000 DCIS cells from 51 patients (median 9 years follow-up for non-BCE cases) were analysed for profiles predictive of BCE. K-means clustering was used to evaluate cellular co-expression of epithelial markers with ER and HER2. Results Only ER, PR and HER2 significantly correlated with BCE. Cluster analysis identified 6 distinct cell groups with different levels of ER, Her2, cMET and SLC7A5. Clusters 1 and 3 were not significant. Clusters 2 and 4 (high ER/low HER2 and SLC7A5/mixed cMET) significantly correlated with low BCE risk ( P = 0.001 and P = 0.034), while cluster 6 (high HER2/low ER, cMET and SLC7A5) correlated with increased risk ( P = 0.018). Cluster 5 (similar to cluster 6, except high SLC7A5) trended towards significance ( P = 0.072). A continuous expression score (Escore) based on these 4 clusters predicted likelihood of BCE (AUC = 0.79, log-rank test P = 5E–05; LOOCV AUC = 0.74, log-rank test P = 0.006). Conclusion Multiplexed spatial analysis of limited tissue is a novel method for biomarker analysis and predicting BCEs. Further validation of Escore is needed in a larger cohort.
AbstractList	Background There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE). Methods Immunofluorescence multiplexing (MxIF) was used to image and quantify 32 cellular biomarkers in FFPE DCIS tissue microarrays. Over 75,000 DCIS cells from 51 patients (median 9 years follow-up for non-BCE cases) were analysed for profiles predictive of BCE. K-means clustering was used to evaluate cellular co-expression of epithelial markers with ER and HER2. Results Only ER, PR and HER2 significantly correlated with BCE. Cluster analysis identified 6 distinct cell groups with different levels of ER, Her2, cMET and SLC7A5. Clusters 1 and 3 were not significant. Clusters 2 and 4 (high ER/low HER2 and SLC7A5/mixed cMET) significantly correlated with low BCE risk ( P = 0.001 and P = 0.034), while cluster 6 (high HER2/low ER, cMET and SLC7A5) correlated with increased risk ( P = 0.018). Cluster 5 (similar to cluster 6, except high SLC7A5) trended towards significance ( P = 0.072). A continuous expression score (Escore) based on these 4 clusters predicted likelihood of BCE (AUC = 0.79, log-rank test P = 5E–05; LOOCV AUC = 0.74, log-rank test P = 0.006). Conclusion Multiplexed spatial analysis of limited tissue is a novel method for biomarker analysis and predicting BCEs. Further validation of Escore is needed in a larger cohort. There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE).BACKGROUNDThere is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE).Immunofluorescence multiplexing (MxIF) was used to image and quantify 32 cellular biomarkers in FFPE DCIS tissue microarrays. Over 75,000 DCIS cells from 51 patients (median 9 years follow-up for non-BCE cases) were analysed for profiles predictive of BCE. K-means clustering was used to evaluate cellular co-expression of epithelial markers with ER and HER2.METHODSImmunofluorescence multiplexing (MxIF) was used to image and quantify 32 cellular biomarkers in FFPE DCIS tissue microarrays. Over 75,000 DCIS cells from 51 patients (median 9 years follow-up for non-BCE cases) were analysed for profiles predictive of BCE. K-means clustering was used to evaluate cellular co-expression of epithelial markers with ER and HER2.Only ER, PR and HER2 significantly correlated with BCE. Cluster analysis identified 6 distinct cell groups with different levels of ER, Her2, cMET and SLC7A5. Clusters 1 and 3 were not significant. Clusters 2 and 4 (high ER/low HER2 and SLC7A5/mixed cMET) significantly correlated with low BCE risk (P = 0.001 and P = 0.034), while cluster 6 (high HER2/low ER, cMET and SLC7A5) correlated with increased risk (P = 0.018). Cluster 5 (similar to cluster 6, except high SLC7A5) trended towards significance (P = 0.072). A continuous expression score (Escore) based on these 4 clusters predicted likelihood of BCE (AUC = 0.79, log-rank test P = 5E-05; LOOCV AUC = 0.74, log-rank test P = 0.006).RESULTSOnly ER, PR and HER2 significantly correlated with BCE. Cluster analysis identified 6 distinct cell groups with different levels of ER, Her2, cMET and SLC7A5. Clusters 1 and 3 were not significant. Clusters 2 and 4 (high ER/low HER2 and SLC7A5/mixed cMET) significantly correlated with low BCE risk (P = 0.001 and P = 0.034), while cluster 6 (high HER2/low ER, cMET and SLC7A5) correlated with increased risk (P = 0.018). Cluster 5 (similar to cluster 6, except high SLC7A5) trended towards significance (P = 0.072). A continuous expression score (Escore) based on these 4 clusters predicted likelihood of BCE (AUC = 0.79, log-rank test P = 5E-05; LOOCV AUC = 0.74, log-rank test P = 0.006).Multiplexed spatial analysis of limited tissue is a novel method for biomarker analysis and predicting BCEs. Further validation of Escore is needed in a larger cohort.CONCLUSIONMultiplexed spatial analysis of limited tissue is a novel method for biomarker analysis and predicting BCEs. Further validation of Escore is needed in a larger cohort. BackgroundThere is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE).MethodsImmunofluorescence multiplexing (MxIF) was used to image and quantify 32 cellular biomarkers in FFPE DCIS tissue microarrays. Over 75,000 DCIS cells from 51 patients (median 9 years follow-up for non-BCE cases) were analysed for profiles predictive of BCE. K-means clustering was used to evaluate cellular co-expression of epithelial markers with ER and HER2.ResultsOnly ER, PR and HER2 significantly correlated with BCE. Cluster analysis identified 6 distinct cell groups with different levels of ER, Her2, cMET and SLC7A5. Clusters 1 and 3 were not significant. Clusters 2 and 4 (high ER/low HER2 and SLC7A5/mixed cMET) significantly correlated with low BCE risk (P = 0.001 and P = 0.034), while cluster 6 (high HER2/low ER, cMET and SLC7A5) correlated with increased risk (P = 0.018). Cluster 5 (similar to cluster 6, except high SLC7A5) trended towards significance (P = 0.072). A continuous expression score (Escore) based on these 4 clusters predicted likelihood of BCE (AUC = 0.79, log-rank test P = 5E–05; LOOCV AUC = 0.74, log-rank test P = 0.006).ConclusionMultiplexed spatial analysis of limited tissue is a novel method for biomarker analysis and predicting BCEs. Further validation of Escore is needed in a larger cohort. There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE). Immunofluorescence multiplexing (MxIF) was used to image and quantify 32 cellular biomarkers in FFPE DCIS tissue microarrays. Over 75,000 DCIS cells from 51 patients (median 9 years follow-up for non-BCE cases) were analysed for profiles predictive of BCE. K-means clustering was used to evaluate cellular co-expression of epithelial markers with ER and HER2. Only ER, PR and HER2 significantly correlated with BCE. Cluster analysis identified 6 distinct cell groups with different levels of ER, Her2, cMET and SLC7A5. Clusters 1 and 3 were not significant. Clusters 2 and 4 (high ER/low HER2 and SLC7A5/mixed cMET) significantly correlated with low BCE risk (P = 0.001 and P = 0.034), while cluster 6 (high HER2/low ER, cMET and SLC7A5) correlated with increased risk (P = 0.018). Cluster 5 (similar to cluster 6, except high SLC7A5) trended towards significance (P = 0.072). A continuous expression score (Escore) based on these 4 clusters predicted likelihood of BCE (AUC = 0.79, log-rank test P = 5E-05; LOOCV AUC = 0.74, log-rank test P = 0.006). Multiplexed spatial analysis of limited tissue is a novel method for biomarker analysis and predicting BCEs. Further validation of Escore is needed in a larger cohort.
Author	McDonough, Elizabeth Badve, Sunil S. Sood, Anup Ginty, Fiona Tan, Puay Hoon Cho, Sanghee Taylor, Marian Chadwick, Chrystal Harris, Adrian L. Gökmen-Polar, Yesim Sui, Yunxia Zavodszky, Maria Gerdes, Michael
Author_xml	– sequence: 1 givenname: Sunil S. orcidid: 0000-0001-8861-9980 surname: Badve fullname: Badve, Sunil S. email: sbadve@iupui.edu organization: Department of Pathology and Laboratory Medicine, Indiana University School of Medicine – sequence: 2 givenname: Sanghee surname: Cho fullname: Cho, Sanghee organization: GE Research – sequence: 3 givenname: Yesim surname: Gökmen-Polar fullname: Gökmen-Polar, Yesim organization: Department of Pathology and Laboratory Medicine, Indiana University School of Medicine – sequence: 4 givenname: Yunxia surname: Sui fullname: Sui, Yunxia organization: GE Research – sequence: 5 givenname: Chrystal surname: Chadwick fullname: Chadwick, Chrystal organization: GE Research – sequence: 6 givenname: Elizabeth surname: McDonough fullname: McDonough, Elizabeth organization: GE Research – sequence: 7 givenname: Anup surname: Sood fullname: Sood, Anup organization: GE Research – sequence: 8 givenname: Marian surname: Taylor fullname: Taylor, Marian organization: Department of Oncology, Cancer and Haematology Centre, Oxford University – sequence: 9 givenname: Maria surname: Zavodszky fullname: Zavodszky, Maria organization: GE Research – sequence: 10 givenname: Puay Hoon surname: Tan fullname: Tan, Puay Hoon organization: Department of Pathology, Singapore General Hospital – sequence: 11 givenname: Michael surname: Gerdes fullname: Gerdes, Michael organization: GE Research – sequence: 12 givenname: Adrian L. orcidid: 0000-0003-1376-8409 surname: Harris fullname: Harris, Adrian L. organization: Department of Oncology, Cancer and Haematology Centre, Oxford University – sequence: 13 givenname: Fiona surname: Ginty fullname: Ginty, Fiona organization: GE Research
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33414541$$D View this record in MEDLINE/PubMed
BookMark	eNp9UU1v1DAUtFAR3S78AQ4oEpf2kPL8FccXpGpboFIrDsDZchx7cZW1F9tB4t_X222B9tCT7Xkzo_GbI3QQYrAIvcVwioH2HzLDDHctEGgBk3rrXqAF5pS0uCfiAC0AQLQgCRyio5xv6lNCL16hQ0qrlDO8QNfX81R8u02xWB-avNXF66nJfh10mZPNTUXH2ZQKGp2MD3Gjd1j2ZW6Oz1eX306a6JohWZ3La_TS6SnbN_fnEv34dPF99aW9-vr5cnV21RomWGmd7nstmXC8AyEGaoECxmQwICQ3oLtx4L2TPa4zkIxJZom2To_WOTL2ki7Rx73vdh42djQ2lKQntU1-o9MfFbVXjyfB_1Tr-FsJ2WGoK1qi43uDFH_NNhe18dnYadLBxjkrwkTHuaQdqdT3T6g3cU6hfk8RDphyAXeJ3v2f6G-Uh01XQr8nmBRzTtYp40tddtwF9JPCoHalqn2pqpaq7kpVXZWSJ9IH92dFdC_KlRzWNv2L_YzqFiK6sxc
CitedBy_id	crossref_primary_10_1016_j_ajpath_2022_09_008 crossref_primary_10_1038_s41568_022_00512_y crossref_primary_10_3233_BD_201063 crossref_primary_10_1158_2767_9764_CRC_24_0287 crossref_primary_10_3389_fmolb_2023_1051491 crossref_primary_10_3389_fonc_2022_918900 crossref_primary_10_3390_cancers17121925 crossref_primary_10_1016_j_jconrel_2022_07_036 crossref_primary_10_1200_EDBK_351207 crossref_primary_10_1210_endocr_bqac027 crossref_primary_10_1002_advs_202402284 crossref_primary_10_1016_j_cpsurg_2023_101361
Cites_doi	10.1056/NEJMoa1804710 10.1016/S1470-2045(12)70503-X 10.2217/bmm.11.57 10.1093/bioinformatics/btq170 10.1186/bcr1397 10.1200/JCO.2015.60.8588 10.1038/modpathol.2017.143 10.1016/S1470-2045(13)70598-9 10.1038/srep06207 10.1016/S0140-6736(14)60488-8 10.1016/S1470-2045(10)70266-7 10.1186/s13058-018-0946-6 10.1186/s12935-017-0427-5 10.1016/S0046-8177(98)90196-4 10.1186/bcr2604 10.18632/oncotarget.14145 10.1158/1078-0432.CCR-18-0842 10.1186/1471-2407-10-108 10.1093/jnci/djr027 10.1073/pnas.1703791114 10.1002/cncr.20979 10.1001/jamasurg.2015.0876 10.1208/s12248-014-9668-6 10.1002/cncr.21069 10.1097/PAP.0000000000000074 10.1001/jamaoncol.2015.2510 10.1093/abbs/gmv075 10.1093/jnci/djq101 10.1038/npjbcancer.2016.14 10.1016/j.breast.2016.09.001 10.1093/ajcp/107.6.684 10.1111/his.13880 10.1245/s10434-017-6018-9 10.1016/j.ejca.2015.05.008 10.1093/jnci/djt067 10.1073/pnas.1300136110 10.1056/NEJMoa1602253 10.1093/jnci/djw256
ContentType	Journal Article
Copyright	The Author(s), under exclusive licence to Cancer Research UK 2021 The Author(s), under exclusive licence to Cancer Research UK 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s), under exclusive licence to Cancer Research UK 2021 – notice: The Author(s), under exclusive licence to Cancer Research UK 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM
DOI	10.1038/s41416-020-01216-6
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection ProQuest Central (subscription) Natural Science Collection ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biological Science Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic ProQuest Central Student MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1532-1827
EndPage	1159
ExternalDocumentID	PMC7961015 33414541 10_1038_s41416_020_01216_6
Genre	Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: U.S. Department of Health & Human Services \| NIH \| National Cancer Institute (NCI) grantid: R01CA194600; R01CA194600 funderid: https://doi.org/10.13039/100000054 – fundername: U.S. Department of Health & Human Services \| NIH \| National Cancer Institute (NCI) – fundername: Cancer Research UK grantid: 18974 – fundername: NCI NIH HHS grantid: R01 CA194600 – fundername: ; – fundername: ; grantid: R01CA194600; R01CA194600
GroupedDBID	--- 0R~ 23N 36B 39C 4.4 406 53G 5GY 5RE 6J9 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AACDK AANZL AASML AATNV AAWTL AAYZH AAZLF ABAKF ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AN0 AOIJS ASPBG AVWKF AXYYD AZFZN BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DNIVK DPUIP DU5 E3Z EAP EBLON EBS EE. EIOEI EMB ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FRJ FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HYE HZ~ IH2 IWAJR JSO JZLTJ KQ8 M1P M7P NAPCQ NQJWS O9- OK1 P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D WH7 WOW ~02 AAFWJ AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB -Q- .55 .GJ 8WZ A6W ABAWZ ABDBF ACUHS AI. B0M CAG CGR COF CUY CVF EAD EAS EBC EBD ECM EIF EJD EMK EMOBN EPL FIZPM J5H M41 NPM SV3 TUS UDS VH1 X7M Y6R ZGI ~8M 3V. 7TO 7U9 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PKEHL PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c474t-fa88a947f56077b3e030112bc0795c0a6db58f9817b3094494e2aefadeff2d893
IEDL.DBID	7RV
ISICitedReferencesCount	10
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000605876500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0007-0920 1532-1827
IngestDate	Tue Nov 04 01:59:54 EST 2025 Sun Nov 09 12:49:14 EST 2025 Tue Oct 07 05:14:00 EDT 2025 Mon Jul 21 05:35:17 EDT 2025 Sat Nov 29 02:47:32 EST 2025 Tue Nov 18 22:00:44 EST 2025 Fri Feb 21 02:38:13 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Language	English
License	Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c474t-fa88a947f56077b3e030112bc0795c0a6db58f9817b3094494e2aefadeff2d893
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0003-1376-8409 0000-0001-8861-9980
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC7961015
PMID	33414541
PQID	2501357089
PQPubID	41855
PageCount	10
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_7961015 proquest_miscellaneous_2476559362 proquest_journals_2501357089 pubmed_primary_33414541 crossref_citationtrail_10_1038_s41416_020_01216_6 crossref_primary_10_1038_s41416_020_01216_6 springer_journals_10_1038_s41416_020_01216_6
PublicationCentury	2000
PublicationDate	2021-03-16
PublicationDateYYYYMMDD	2021-03-16
PublicationDate_xml	– month: 03 year: 2021 text: 2021-03-16 day: 16
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	British journal of cancer
PublicationTitleAbbrev	Br J Cancer
PublicationTitleAlternate	Br J Cancer
PublicationYear	2021
Publisher	Nature Publishing Group UK Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group
References	Sagara, Mallory, Wong, Aydogan, DeSantis, Barry (CR16) 2015; 150 Fallowfield, Francis, Catt, Mackenzie, Jenkins (CR8) 2012; 13 Nasir, Holzer, Chen, Man, Schade (CR25) 2017; 17 Wapnir, Dignam, Fisher, Mamounas, Anderson, Julian (CR3) 2011; 103 Gerdes, Gokmen-Polar, Sui, Pang, LaPlante, Harris (CR13) 2018; 31 Bartlett, Thomas, Ross, Seitz, Ring, Beck (CR27) 2010; 12 Wilkerson, Hayes (CR32) 2010; 26 Leung, Nielsen, Zabaglo, Arun, Badve, Bane (CR39) 2019; 75 Collins, Tamimi, Baer, Connolly, Colditz, Schnitt (CR6) 2005; 103 Wright, Hou, Xu, Cortez, Potma, Tromberg (CR22) 2017; 114 Yang, He, Liu, He, Yang, Du (CR23) 2015; 47 Cardoso, van’t Veer, Bogaerts, Slaets, Viale, Delaloge (CR34) 2016; 375 Ebctcg, McGale, Taylor, Correa, Cutter, Duane (CR1) 2014; 383 Kerlikowske, Molinaro, Gauthier, Berman, Waldman, Bennington (CR17) 2010; 102 Narod, Iqbal, Giannakeas, Sopik, Sun (CR36) 2015; 1 Solin, Gray, Baehner, Butler, Hughes, Yoshizawa (CR19) 2013; 105 Hicks, Janarthanan, Vardarajan, Kulkarni, Khoury, Dim (CR26) 2010; 10 Bremer, Whitworth, Patel, Savala, Barry, Lyle (CR18) 2018; 24 Gerdes, Sevinsky, Sood, Adak, Bello, Bordwell (CR31) 2013; 110 Șenbabaoğlu, Michailidis, Li (CR33) 2014; 4 Solin, Gray, Hughes, Wood, Lowen, Badve (CR15) 2015; 33 Kochel, Reader, Ma, Kundu, Fulton (CR28) 2017; 8 El Ansari, Craze, Miligy, Diez-Rodriguez, Nolan, Ellis (CR40) 2018; 20 Groen, Elshof, Visser, Rutgers, Winter-Warnars, Lips (CR9) 2017; 31 Grimm, Ryser, Partridge, Thompson, Thomas, Wesseling (CR10) 2017; 24 Sparano, Gray, Makower, Pritchard, Albain, Hayes (CR35) 2018; 379 Badve, A’Hern, Ward, Millis, Pinder, Ellis (CR11) 1998; 29 Sanders, Schuyler, Dupont, Page (CR4) 2005; 103 Esserman, Thompson, Reid, Nelson, Ransohoff, Welch (CR37) 2014; 15 Jones (CR5) 2006; 8 CR20 Wakasugi, Kobayashi, Tamaki, Ito, Miyashiro, Komoike (CR24) 1997; 107 Delou, Vignal, Indio-do-Brasil, Accioly, da Silva, Piranda (CR30) 2017; 9 Badve, Gokmen-Polar (CR12) 2015; 22 Cuzick, Sestak, Pinder, Ellis, Forsyth, Bundred (CR2) 2011; 12 Mao, Unadkat (CR29) 2015; 17 Gokmen-Polar, Nakshatri, Badve (CR21) 2011; 5 Elshof, Tryfonidis, Slaets, van Leeuwen-Stok, Skinner, Dif (CR7) 2015; 51 Harrison, Hwang, Partridge, Thompson, Schnitt (CR14) 2018; 31 Leung, Nielsen, Zabaglo, Arun, Badve, Bane (CR38) 2016; 2 S Badve (1216_CR12) 2015; 22 Y Gokmen-Polar (1216_CR21) 2011; 5 LE Elshof (1216_CR7) 2015; 51 EJ Groen (1216_CR9) 2017; 31 HJ Wright (1216_CR22) 2017; 114 JM Bartlett (1216_CR27) 2010; 12 SCY Leung (1216_CR38) 2016; 2 Ebctcg (1216_CR1) 2014; 383 MD Wilkerson (1216_CR32) 2010; 26 JL Jones (1216_CR5) 2006; 8 R El Ansari (1216_CR40) 2018; 20 A Nasir (1216_CR25) 2017; 17 Y Sagara (1216_CR16) 2015; 150 SA Narod (1216_CR36) 2015; 1 MJ Gerdes (1216_CR13) 2018; 31 IL Wapnir (1216_CR3) 2011; 103 LC Collins (1216_CR6) 2005; 103 Y Șenbabaoğlu (1216_CR33) 2014; 4 T Bremer (1216_CR18) 2018; 24 C Yang (1216_CR23) 2015; 47 LJ Esserman (1216_CR37) 2014; 15 SCY Leung (1216_CR39) 2019; 75 1216_CR20 DG Hicks (1216_CR26) 2010; 10 ME Sanders (1216_CR4) 2005; 103 L Fallowfield (1216_CR8) 2012; 13 LJ Grimm (1216_CR10) 2017; 24 BT Harrison (1216_CR14) 2018; 31 JMA Delou (1216_CR30) 2017; 9 K Kerlikowske (1216_CR17) 2010; 102 TJ Kochel (1216_CR28) 2017; 8 LJ Solin (1216_CR15) 2015; 33 F Cardoso (1216_CR34) 2016; 375 J Cuzick (1216_CR2) 2011; 12 MJ Gerdes (1216_CR31) 2013; 110 JA Sparano (1216_CR35) 2018; 379 S Badve (1216_CR11) 1998; 29 LJ Solin (1216_CR19) 2013; 105 E Wakasugi (1216_CR24) 1997; 107 Q Mao (1216_CR29) 2015; 17
References_xml	– volume: 379 start-page: 111 year: 2018 end-page: 121 ident: CR35 article-title: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1804710 – volume: 13 start-page: 1183 year: 2012 end-page: 1185 ident: CR8 article-title: Time for a low-risk DCIS trial: harnessing public and patient involvement publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(12)70503-X – volume: 5 start-page: 661 year: 2011 end-page: 671 ident: CR21 article-title: Biomarkers for breast cancer stem cells: the challenges ahead publication-title: Biomark. Med. doi: 10.2217/bmm.11.57 – volume: 26 start-page: 1572 year: 2010 end-page: 1573 ident: CR32 article-title: ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq170 – volume: 8 year: 2006 ident: CR5 article-title: Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective publication-title: Breast Cancer Res. doi: 10.1186/bcr1397 – volume: 33 start-page: 3938 year: 2015 end-page: 3944 ident: CR15 article-title: Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.60.8588 – volume: 9 start-page: 415 year: 2017 end-page: 428 ident: CR30 article-title: Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis publication-title: Breast Cancer (Dove Med Press). – volume: 31 start-page: 406 year: 2018 end-page: 417 ident: CR13 article-title: Single-cell heterogeneity in ductal carcinoma in situ of breast publication-title: Mod. Pathol. doi: 10.1038/modpathol.2017.143 – volume: 15 start-page: e234 year: 2014 end-page: e242 ident: CR37 article-title: Addressing overdiagnosis and overtreatment in cancer: a prescription for change publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(13)70598-9 – volume: 4 year: 2014 ident: CR33 article-title: Critical limitations of consensus clustering in class discovery publication-title: Sci. Rep. doi: 10.1038/srep06207 – volume: 383 start-page: 2127 year: 2014 end-page: 2135 ident: CR1 article-title: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(14)60488-8 – volume: 12 start-page: 21 year: 2011 end-page: 29 ident: CR2 article-title: Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(10)70266-7 – volume: 20 year: 2018 ident: CR40 article-title: The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours publication-title: Breast Cancer Res. doi: 10.1186/s13058-018-0946-6 – volume: 17 year: 2017 ident: CR25 article-title: Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies publication-title: Cancer Cell Int. doi: 10.1186/s12935-017-0427-5 – volume: 29 start-page: 915 year: 1998 end-page: 923 ident: CR11 article-title: Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up publication-title: Hum. Pathol. doi: 10.1016/S0046-8177(98)90196-4 – volume: 12 year: 2010 ident: CR27 article-title: Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy publication-title: Breast Cancer Res. doi: 10.1186/bcr2604 – volume: 31 start-page: 70 year: 2018 ident: CR14 article-title: Variability in diagnostic threshold for comedo necrosis among pathologists: implications for patient eligibility for active surveillance trials of DCIS publication-title: Mod. Pathol. – volume: 8 start-page: 6540 year: 2017 end-page: 6554 ident: CR28 article-title: Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.14145 – volume: 24 start-page: 5895 year: 2018 end-page: 5901 ident: CR18 article-title: A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-0842 – volume: 10 year: 2010 ident: CR26 article-title: The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence publication-title: BMC Cancer doi: 10.1186/1471-2407-10-108 – volume: 103 start-page: 478 year: 2011 end-page: 488 ident: CR3 article-title: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djr027 – volume: 114 start-page: E6556 year: 2017 end-page: E6565 ident: CR22 article-title: CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1703791114 – volume: 103 start-page: 1778 year: 2005 end-page: 1784 ident: CR6 article-title: Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study publication-title: Cancer doi: 10.1002/cncr.20979 – volume: 150 start-page: 739 year: 2015 end-page: 745 ident: CR16 article-title: Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study publication-title: JAMA Surg. doi: 10.1001/jamasurg.2015.0876 – volume: 17 start-page: 65 year: 2015 end-page: 82 ident: CR29 article-title: Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport–an update publication-title: AAPS J. doi: 10.1208/s12248-014-9668-6 – volume: 103 start-page: 2481 year: 2005 end-page: 2484 ident: CR4 article-title: The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up publication-title: Cancer doi: 10.1002/cncr.21069 – volume: 22 start-page: 294 year: 2015 end-page: 302 ident: CR12 article-title: Tumor heterogeneity in breast cancer publication-title: Adv. Anat. Pathol. doi: 10.1097/PAP.0000000000000074 – volume: 1 start-page: 888 year: 2015 end-page: 896 ident: CR36 article-title: Breast cancer mortality after a diagnosis of ductal carcinoma in situ publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2015.2510 – volume: 47 start-page: 788 year: 2015 end-page: 794 ident: CR23 article-title: Down-regulation of CEACAM1 in breast cancer publication-title: Acta Biochim. Biophys. Sin. (Shanghai). doi: 10.1093/abbs/gmv075 – volume: 102 start-page: 627 year: 2010 end-page: 637 ident: CR17 article-title: Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djq101 – volume: 2 year: 2016 ident: CR38 article-title: Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration publication-title: NPJ Breast Cancer doi: 10.1038/npjbcancer.2016.14 – volume: 31 start-page: 274 year: 2017 end-page: 283 ident: CR9 article-title: Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS) publication-title: Breast doi: 10.1016/j.breast.2016.09.001 – volume: 107 start-page: 684 year: 1997 end-page: 691 ident: CR24 article-title: p21(Waf1/Cip1) and p53 protein expression in breast cancer publication-title: Am. J. Clin. Pathol. doi: 10.1093/ajcp/107.6.684 – volume: 75 start-page: 225 year: 2019 end-page: 235 ident: CR39 article-title: Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration publication-title: Histopathology doi: 10.1111/his.13880 – volume: 24 start-page: 3534 year: 2017 end-page: 3540 ident: CR10 article-title: Surgical Upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-017-6018-9 – volume: 51 start-page: 1497 year: 2015 end-page: 1510 ident: CR7 article-title: Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ—The LORD study publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2015.05.008 – volume: 105 start-page: 701 year: 2013 end-page: 710 ident: CR19 article-title: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djt067 – volume: 110 start-page: 11982 year: 2013 end-page: 11987 ident: CR31 article-title: Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue publication-title: Proc. Natl Acad. Sci. USA. doi: 10.1073/pnas.1300136110 – ident: CR20 – volume: 375 start-page: 717 year: 2016 end-page: 729 ident: CR34 article-title: 70-Gene signature as an aid to treatment decisions in early-stage breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1602253 – volume: 4 year: 2014 ident: 1216_CR33 publication-title: Sci. Rep. doi: 10.1038/srep06207 – volume: 12 start-page: 21 year: 2011 ident: 1216_CR2 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(10)70266-7 – volume: 103 start-page: 478 year: 2011 ident: 1216_CR3 publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djr027 – volume: 379 start-page: 111 year: 2018 ident: 1216_CR35 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1804710 – volume: 20 year: 2018 ident: 1216_CR40 publication-title: Breast Cancer Res. doi: 10.1186/s13058-018-0946-6 – volume: 114 start-page: E6556 year: 2017 ident: 1216_CR22 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1703791114 – volume: 12 year: 2010 ident: 1216_CR27 publication-title: Breast Cancer Res. doi: 10.1186/bcr2604 – volume: 375 start-page: 717 year: 2016 ident: 1216_CR34 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1602253 – volume: 31 start-page: 406 year: 2018 ident: 1216_CR13 publication-title: Mod. Pathol. doi: 10.1038/modpathol.2017.143 – volume: 24 start-page: 3534 year: 2017 ident: 1216_CR10 publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-017-6018-9 – volume: 150 start-page: 739 year: 2015 ident: 1216_CR16 publication-title: JAMA Surg. doi: 10.1001/jamasurg.2015.0876 – volume: 17 year: 2017 ident: 1216_CR25 publication-title: Cancer Cell Int. doi: 10.1186/s12935-017-0427-5 – volume: 9 start-page: 415 year: 2017 ident: 1216_CR30 publication-title: Breast Cancer (Dove Med Press). – volume: 47 start-page: 788 year: 2015 ident: 1216_CR23 publication-title: Acta Biochim. Biophys. Sin. (Shanghai). doi: 10.1093/abbs/gmv075 – volume: 103 start-page: 1778 year: 2005 ident: 1216_CR6 publication-title: Cancer doi: 10.1002/cncr.20979 – volume: 2 year: 2016 ident: 1216_CR38 publication-title: NPJ Breast Cancer doi: 10.1038/npjbcancer.2016.14 – volume: 105 start-page: 701 year: 2013 ident: 1216_CR19 publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djt067 – volume: 26 start-page: 1572 year: 2010 ident: 1216_CR32 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq170 – ident: 1216_CR20 doi: 10.1093/jnci/djw256 – volume: 33 start-page: 3938 year: 2015 ident: 1216_CR15 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.60.8588 – volume: 13 start-page: 1183 year: 2012 ident: 1216_CR8 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(12)70503-X – volume: 31 start-page: 70 year: 2018 ident: 1216_CR14 publication-title: Mod. Pathol. – volume: 102 start-page: 627 year: 2010 ident: 1216_CR17 publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djq101 – volume: 8 start-page: 6540 year: 2017 ident: 1216_CR28 publication-title: Oncotarget doi: 10.18632/oncotarget.14145 – volume: 103 start-page: 2481 year: 2005 ident: 1216_CR4 publication-title: Cancer doi: 10.1002/cncr.21069 – volume: 75 start-page: 225 year: 2019 ident: 1216_CR39 publication-title: Histopathology doi: 10.1111/his.13880 – volume: 383 start-page: 2127 year: 2014 ident: 1216_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(14)60488-8 – volume: 22 start-page: 294 year: 2015 ident: 1216_CR12 publication-title: Adv. Anat. Pathol. doi: 10.1097/PAP.0000000000000074 – volume: 1 start-page: 888 year: 2015 ident: 1216_CR36 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2015.2510 – volume: 51 start-page: 1497 year: 2015 ident: 1216_CR7 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2015.05.008 – volume: 29 start-page: 915 year: 1998 ident: 1216_CR11 publication-title: Hum. Pathol. doi: 10.1016/S0046-8177(98)90196-4 – volume: 5 start-page: 661 year: 2011 ident: 1216_CR21 publication-title: Biomark. Med. doi: 10.2217/bmm.11.57 – volume: 24 start-page: 5895 year: 2018 ident: 1216_CR18 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-0842 – volume: 31 start-page: 274 year: 2017 ident: 1216_CR9 publication-title: Breast doi: 10.1016/j.breast.2016.09.001 – volume: 107 start-page: 684 year: 1997 ident: 1216_CR24 publication-title: Am. J. Clin. Pathol. doi: 10.1093/ajcp/107.6.684 – volume: 17 start-page: 65 year: 2015 ident: 1216_CR29 publication-title: AAPS J. doi: 10.1208/s12248-014-9668-6 – volume: 8 year: 2006 ident: 1216_CR5 publication-title: Breast Cancer Res. doi: 10.1186/bcr1397 – volume: 15 start-page: e234 year: 2014 ident: 1216_CR37 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(13)70598-9 – volume: 10 year: 2010 ident: 1216_CR26 publication-title: BMC Cancer doi: 10.1186/1471-2407-10-108 – volume: 110 start-page: 11982 year: 2013 ident: 1216_CR31 publication-title: Proc. Natl Acad. Sci. USA. doi: 10.1073/pnas.1300136110
SSID	ssj0009087
Score	2.4129386
Snippet	Background There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE). Methods Immunofluorescence multiplexing... There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE). Immunofluorescence multiplexing (MxIF) was used to... BackgroundThere is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE).MethodsImmunofluorescence multiplexing... There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE).BACKGROUNDThere is limited knowledge about DCIS...
SourceID	pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1150
SubjectTerms	631/67/1347 692/53/2422 Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer Research Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - therapy Carcinoma, Intraductal, Noninfiltrating - metabolism Carcinoma, Intraductal, Noninfiltrating - pathology Carcinoma, Intraductal, Noninfiltrating - therapy Cluster analysis Combined Modality Therapy Drug Resistance Epidemiology ErbB-2 protein Female Follow-Up Studies Humans Immunofluorescence Mastectomy - methods Middle Aged Molecular Medicine Oncology Prognosis Retrospective Studies Survival Rate
Title	Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast
URI	https://link.springer.com/article/10.1038/s41416-020-01216-6 https://www.ncbi.nlm.nih.gov/pubmed/33414541 https://www.proquest.com/docview/2501357089 https://www.proquest.com/docview/2476559362 https://pubmed.ncbi.nlm.nih.gov/PMC7961015
Volume	124
WOSCitedRecordID	wos000605876500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: M7P dateStart: 20190101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7RV dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 8C1 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BixAXyqsQKKsgcQCBVSdxbOdUtUsrOHS1Kg_tLXIcW6wESWl2-f3MONldLRW9cPHBduQ4M_aMPV--AXjNTWald55Z5ysmas9ZlZuaaWlS1ChRKKNDsgk1mejZrJgOF27dAKtc7Ylho65bS3fkh2iqkyxXXBdHl78YZY2i6OqQQuM27CZku1Gf1cW3Deku1z1nJl3HFSkffprhmT7sRIKuCKPDE7GaSSa3DdM1b_M6aPKvyGkwSGd7_zuVB3B_cEXj4153HsIt1zyCu-dDsP0xnIefc1lgcpg3cUfYa-xPiI_ABtrFWEt0sVhpKSVR0_40VIfjLOM3H8afPr-NWx9XhHtfPIGvZ6dfxh_ZkH2BWaHEgnmjtSmE8vhdlaoyFw5PaWW5KnLLjayrXPtCJ9iGZ0RRCJca503tvE9rdIP2YadpG_cM4kQ6a1LCsYpMWDSPXNV4klJOWSusziJIVp--tAM1OWXI-FGGEHmmy15cJYqrDOIqZQTv1s9c9sQcN_Y-WImiHBZpV27kEMGrdTMuL4qZmMa1S-wjlMwp62EawdNeAdbDZegBiFwkEagt1Vh3IOru7ZZm_j1QeKsC3dYkj-D9Sok2r_XvWTy_eRYv4F5KiBtCG8oD2FlcLd1LuGN_L-bd1SgsDSpnKpQaSz1ORrB7cjqZXowI9Tr9A-NAGAs
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL2qCgI2vB-BAkECCQRWE8eJnQVCqKXqqJ0REkWaXeo4thgJktLMgPgpvpF7nWRGQ0V3XbC1HSWOT-4jPj4X4HmkE5M565ixrmSichErU10xlWmOiBK51MoXm5CTiZpO848b8Hs4C0O0ysEmekNdNYb-kW-jq46TVEYqf3fynVHVKNpdHUpodLA4sL9-YsrWvh3t4vq-4Hzvw9HOPuurCjAjpJgzp5XSuZAOfb2UZWJ9UsBLE8k8NZHOqjJVLlcx9mHuI3JhubZOV9Y5XikSX0KTfwntuCQKmZzKlchvpDqNTvr9l_OoP6QTJWq7FTGGPoySNVJRy1i27gjPRLdnSZp_7dR6B7h34397dTfheh9qh--7b-MWbNj6NlwZ92SCOzD2h4-ZV6qY1WFL3HIcT4wWr3bahthKcrjYaKjkUt1809SG81qEL3d3Rp9ehY0LS-L1z-_C5wuZzD3YrJvaPoAwzqzRnHi6IhEG3X8kK8wUpZXGCKOSAOJhqQvTS69TBZCvhacAJKro4FEgPAoPjyIL4PXympNOeOTc0VvD0he9EWqL1boH8GzZjeaD9oR0bZsFjhEyS6mqIw_gfge45e0SjHBEKuIA5BoUlwNImny9p5598RLlMsewPE4DeDOAdvVY_57Fw_Nn8RSu7h-ND4vD0eTgEVzjxC4iZmW2BZvz04V9DJfNj_msPX3iP8sQji8azH8AAwpvkA
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VLaq48H4ECgQJJBC1NnGc2DkgBN2uWJWuVjyk3oLj2OpKJSnNLoi_xq9jJo9dLRW99cDVdpQ4_jyesT9_A_As0JFJnHXMWJczUbiA5bEumEo0R0SJVGrVJJuQk4k6OkqnG_C7vwtDtMreJjaGuqgM7ZEPcKkOo1gGKh24jhYxHY7enH5nlEGKTlr7dBotRA7sr58YvtWvx0Mc6-ecj_Y_771nXYYBZoQUc-a0UjoV0uG6L2Ue2SZA4LkJZBqbQCdFHiuXqhDrMA4SqbBcW6cL6xwvFAkxofnfkuhk4Ozaerc_mX5cSf4GqlXspM3AlAfdlZ0gUoNahOgIMQrdSFMtYcn6snjO1z1P2fzr3LZZDkfX_-cfeQOudU64_7adNTdhw5a3YPuwoxnchsPmWjJrNCxmpV8T6xzbE9el0UGtfSwloVwsNJSMqay-aSrDfi38F8O98aeXfuX8nBj_8zvw5VI6cxc2y6q098EPE2s0JwaviIRBxyCQBcaQ0kpjhFGRB2E_7JnpRNkpN8hJ1pADIpW1UMkQKlkDlSzx4NXymdNWkuTC1js9DLLOPNXZCgMePF1Wo2Gh0yJd2mqBbYRMYsr3yD2414Jv-boIfR8Ri9ADuQbLZQMSLV-vKWfHjXi5TNFhD2MPdnsArz7r3714cHEvnsA2Yjj7MJ4cPISrnGhHRLlMdmBzfrawj-CK-TGf1WePuznqw9fLRvMfx1J5sQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multi-protein+spatial+signatures+in+ductal+carcinoma+in+situ+%28DCIS%29+of+breast&rft.jtitle=British+journal+of+cancer&rft.au=Badve%2C+Sunil+S&rft.au=Cho%2C+Sanghee&rft.au=G%C3%B6kmen-Polar%2C+Yesim&rft.au=Sui%2C+Yunxia&rft.date=2021-03-16&rft.eissn=1532-1827&rft.volume=124&rft.issue=6&rft.spage=1150&rft_id=info:doi/10.1038%2Fs41416-020-01216-6&rft_id=info%3Apmid%2F33414541&rft.externalDocID=33414541
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon